Think triple (ICS/LABA/LAMA),
think Trimbow®
The only extrafine formulation ICS/LABA/LAMA combination1-3
Designed to reach the large and small airways1,2,4
The only ICS/LABA/LAMA combination available in both a pMDI and NEXThaler (DPI) for the maintenance treatment of adult patients with moderate to severe COPD who require triple therapy1–3
Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2

Each dose contains three molecules:1,2
- Beclometasone
- Formoterol
- Glycopyrronium
Extrafine formulation like Fostair® (beclometasone/formoterol)1,2,5,6
Choice of pMDI or NEXThaler device to meet your patients’ needs1,2
- LAMA (Spiriva® HandiHaler®)7
- ICS/LABA (Fostair pMDI 100/6) – secondary endpoint8
- LABA/LAMA (Ultibro® Breezhaler®)9
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.